Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 8, 2026BMC ImmunologyOpen Access

SDF4 is a potential biomarker for diagnosis and severity assessment in patients with systemic lupus erythematosus

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXi ChenSoochow UniversityXYXuanzhe YangSoochow UniversityJCJing ChenThe Coordinating Center

Discussion

Loading...

Member takes

Implication

Case-control study demonstrates elevated serum SDF4 accurately distinguishes systemic lupus erythematosus from healthy controls, indicating its potential as a diagnostic and severity biomarker.

Key Points

  • To evaluate whether stromal cell-derived factor 4 (SDF4) can serve as a clinical biomarker for diagnosing systemic lupus erythematosus (SLE), tracking severity, and assessing prognosis.
  • Measured SDF4 expression in peripheral blood mononuclear cells (PBMCs) and serum from SLE patients and healthy controls using RT-qPCR, Western blot, and ELISA.
  • Evaluated diagnostic accuracy and clinical associations using Spearman's correlation, logistic regression, and receiver operating characteristic (ROC) curve analysis.
  • SDF4 mRNA and protein levels in PBMCs were significantly upregulated (P < 0.05), and elevated serum SDF4 was strongly associated with SLE presence (Z = -6.707, P < 0.001).
  • Serum SDF4 differentiated SLE patients from healthy controls with an AUC of 0.954 (95.83% sensitivity, 80.00% specificity at 43.18 pg/mL cut-off), rising to an AUC of 0.975 when combined with anti-dsDNA antibody titers.
  • Circulating SDF4 concentrations correlated positively with multi-organ involvement, including arthritis and anemia.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd74958e84d0ff5b45c66https://doi.org/10.1186/s12865-026-00890-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treat‐To‐Target: Emergence of Second‐Generation CD 40 L Inhibitors for Treatment of SLE —Identifying Beneficial Patient Candidates for CD 40 L Inhibitors in a Cross‐Sectional SLE Cohort2025 · 3 citations
  2. 2Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE2025 · 4 citations
  3. 3CLEC4E as a molecular biomarker in systemic lupus erythematosus: integrating bioinformatics and clinical data to assess its prognostic value2025 · 2 citations
  4. 4Elevated Serum Soluble Syndecan-1 Is Associated with Lupus Nephritis Flares: A Cross-Sectional Study2026
  5. 5Study of C-X-C chemokine receptor type 4 in systemic lupus erythematosus expression on circulating B cells as a potential biomarker for systemic lupus erythematosus activity2025